Panel Discussion: Defining Success in Antigen Specific Immune Tolerance
- What does true success look like in ASIT – single-dose cures, durable remission, or reduced treatment burden?
- How can the field align on shared clinical benchmarks as we move from preclinical to human data
- What lessons can be drawn from broader immunology approaches, such as B cell depletion, allergy learnings and tolerance induction?
- How do current clinical outcomes compare between targeted tolerance and broader immunoregulatory mechanisms?